International Flavors & Fragrances (IFF)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-10-29
$93.02+2.43%
Close 2026-10-30 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-10-29
Research Workspace
Put IFF beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Revenue grows to about $10.65 billion in 2026: Revenue guidance: $7.4B to $7.6B.
View ThesisRevenue is contracting — down about 4% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskIFF’s case rests on strong recent performance, though revenue growth remains weak. Revenue rose 2% year over year in Q2 FY2026 after declining earlier. The latest quarter missed on earnings, with non-GAAP EPS 28.1% below consensus. IFF trades at 23× P/E versus 17× for peers and 21× historically. The market is pricing in more growth than our forecast, leaving expectations full. A 21% next-quarter miss probability adds risk, alongside the broken 2026 revenue pillar. Peer multiples imply a price about 23% below where it trades. The thesis has broken; this read is provisional.
Trailing returns as of 2026-10-30. IFF is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 21 analysts currently covering IFF (as of Oct 2026).
Based on 6 Wall Street analysts offering 12-month price targets for IFF in the last 4 months.
Continue this research
Compare IFF with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| IFF Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put IFF next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Maintain disciplined capital allocation and financial flexibility
Poor capital allocation impacts financial flexibility and growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $93.02
The last 12 months of price, then the range of analyst 12-month targets from today’s $93.02.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Optimize portfolio through divestitures
Q2 2026 miss indicates potential issues with portfolio optimization.
Threatens: Improve financial flexibility
Lowered guidance impacts financial performance and flexibility.
Advances: Optimize portfolio through divestitures
Divestiture aligns with optimizing portfolio strategy.
Advances: Drive financial performance with innovation
Earnings beat indicates strong financial performance.
Advances: Drive financial performance with innovation
New product launch enhances innovation efforts.
Advances: Drive financial performance with innovation
Q4 earnings beat and sales rise support financial performance.
Advances: Optimize portfolio through divestitures
Divestiture of cosmetics business aligns with portfolio optimization.